| GENERIC NAME | This data is not available for free |
| STRUCTURE |
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)- 1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate |
| INDICATION'S |
ONCOLOGY - Leukemia>Acute Lymphoblastic Leukemia - Leukemia>Chronic Myeloid Leukemia |
| MECHANISM OF ACTION |
BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRb. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. |
| STATUS | Approved: 06.29.06. US Expiration: 04.13.2020 |
| COMPANY | This data is not available for free |
| PATENT NUMBER | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |